Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1995 May;4(7):S26–S30. doi: 10.1155/S0962935195000810

A review of the tolerability and safety of levocabastine eye drops and nasal spray. Implications for patient management

Peter H Howarth 1
PMCID: PMC2365682  PMID: 18475686

Abstract

Levocabastine is a highly potent and selective H1-receptor antagonist specifically developed for topical administration by ocular and nasal routes. The clinical effects of levocabastine occur rapidly and are predominantly due to local antihistaminic effects at the site of application. Clinically, levocabastine is well tolerated with an adverse effect profile comparable with that of sodium cromoglycate and placebo. As might be expected from the route of drug administration, local irritation is the most frequent adverse event seen with levocabastine eye drops and nasal spray with an incidence comparable with that in placebo-treated controls. Intranasal application of levocabastine has been shown to have no adverse effect on ciliary activity both in vitro and in vivo, while ocular administration has not been shown to have any significant or consistent adverse effect in both animal and human studies. At therapeutic doses, levocabastine appears to be devoid of significant systemic activity producing no apparent effects on cardiovascular, psychomotor and cognitive function. Since levocabastine undergoes little hepatic metabolism, and only low plasma levels of the drug are attained following topical administration, drug interactions are unlikely.

Full Text

The Full Text of this article is available as a PDF (473.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abelson M. B., Paradis A., George M. A., Smith L. M., Maguire L., Burns R. Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis. Arch Ophthalmol. 1990 Apr;108(4):520–524. doi: 10.1001/archopht.1990.01070060068051. [DOI] [PubMed] [Google Scholar]
  2. Abelson M. B., Smith L. M. Levocabastine. Evaluation in the histamine and compound 48/80 models of ocular allergy in humans. Ophthalmology. 1988 Nov;95(11):1494–1497. [PubMed] [Google Scholar]
  3. Arriaga F., Rombaut N. Absence of central effects with levocabastine eye drops. Allergy. 1990 Oct;45(7):552–554. doi: 10.1111/j.1398-9995.1990.tb00531.x. [DOI] [PubMed] [Google Scholar]
  4. Badhwar A. K., Druce H. M. Allergic rhinitis. Med Clin North Am. 1992 Jul;76(4):789–803. doi: 10.1016/s0025-7125(16)30326-1. [DOI] [PubMed] [Google Scholar]
  5. Bahmer F. A., Ruprecht K. W. Safety and efficacy of topical levocabastine compared with oral terfenadine. Ann Allergy. 1994 May;72(5):429–434. [PubMed] [Google Scholar]
  6. Dechant K. L., Goa K. L. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs. 1991 Feb;41(2):202–224. doi: 10.2165/00003495-199141020-00006. [DOI] [PubMed] [Google Scholar]
  7. Friedlaender M. H. Current concepts in ocular allergy. Ann Allergy. 1991 Jul;67(1):5-10, 13. [PubMed] [Google Scholar]
  8. Janssens M. Efficacy of levocabastine in conjunctival provocation studies. Doc Ophthalmol. 1992;82(4):341–351. doi: 10.1007/BF00161022. [DOI] [PubMed] [Google Scholar]
  9. Merkus F. W., Schüsler-van Hees M. T. Influence of levocabastine suspension on ciliary beat frequency and mucociliary clearance. Allergy. 1992 Jun;47(3):230–233. doi: 10.1111/j.1398-9995.1992.tb00655.x. [DOI] [PubMed] [Google Scholar]
  10. Palma-Carlos A. G., Palma-Carlos M. L., Rombaut N. The effect of levocabastine nasal spray in nasal provocation tests. Int J Clin Pharmacol Res. 1988;8(1):25–30. [PubMed] [Google Scholar]
  11. Rimås M., Kjellman N. I., Blychert L. O., Björkstén B. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests. Allergy. 1990 Jan;45(1):18–21. doi: 10.1111/j.1398-9995.1990.tb01079.x. [DOI] [PubMed] [Google Scholar]
  12. Rombaut N., Bhatti J. Z., Curran S., Hindmarch I. Effects of topical administration of levocabastine on psychomotor and cognitive function. Ann Allergy. 1991 Jul;67(1):75–79. [PubMed] [Google Scholar]
  13. Stokes T. C., Feinberg G. Rapid onset of action of levocabastine eye-drops in histamine-induced conjunctivitis. Clin Exp Allergy. 1993 Sep;23(9):791–794. doi: 10.1111/j.1365-2222.1993.tb00368.x. [DOI] [PubMed] [Google Scholar]
  14. Topical levocabastine compared with oral loratadine for the treatment of seasonal allergic rhinoconjunctivitis. Swedish GP Allergy Team. Allergy. 1994 Sep;49(8):611–615. doi: 10.1111/j.1398-9995.1994.tb00127.x. [DOI] [PubMed] [Google Scholar]
  15. Vermeulen J., Mercer M. Comparison of the efficacy and tolerability of topical levocabastine and sodium cromoglycate in the treatment of seasonal allergic rhinoconjunctivitis in children. Pediatr Allergy Immunol. 1994 Nov;5(4):209–213. doi: 10.1111/j.1399-3038.1994.tb00241.x. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES